Latest News About Samsung Bioepis

Here’s the latest I can share about Samsung Bioepis based on recent public disclosures up to 2026.

Key recent developments

• FDA review milestones: In 2025, Samsung Bioepis announced that its SB5 adalimumab biosimilar candidate had an FDA biosimilar application accepted for review. This marks progress toward a potential US market entry for SB5. In 2026, the company reported that SB3, a trastuzumab biosimilar candidate, also had an FDA acceptance for review under the 351(k) pathway, which would position SB3 as its first oncology biosimilar under US regulatory review; Merck/MSD would be the US commercialization partner if approved. These actions reflect ongoing US regulatory activity for multiple biosimilar candidates in Samsung Bioepis’ pipeline.[1][2]
• Pipeline and strategic positioning: Samsung Bioepis has publicly outlined a multi-biosimilar strategy aiming to broaden its portfolio across immunology, oncology, ophthalmology, and other areas, with several candidates advancing in late-stage development or regulatory review. Updates from investor-focused presentations indicate ongoing expansion of its pipeline toward 2030, including candidates in immunology and oncology and potential future oncology references such as dupilumab, guselkumab, ixekizumab, and others in various stages of development.[3]
• Global regulatory and market activity: Samsung Bioepis maintains a broad regulatory footprint, including interactions with the FDA for multiple candidates and collaborations with partners like Biogen for ophthalmology biosimilars in some regions; the company has also pursued WHO prequalification milestones for certain products in collaboration with Biogen. In addition, ongoing regulatory interactions and market activity include European and other global markets, with new product approvals or regulatory considerations often highlighted in company press releases and industry coverage.[5][6][9]

What this means for patients and the market

• US access timeline uncertainty: FDA review acceptance is a critical milestone, but final approval decisions depend on complete review outcomes and potential post-approval commitments, which means timelines for patients to access these biosimilars in the US can still be several years away.[2]
• Competitive biosimilar landscape: Samsung Bioepis remains a notable player in the biosimilars space, complementing existing products from other manufacturers, with ongoing regulatory progress across multiple molecules and indications.[3][5]

Illustrative example

• SB3 (trastuzumab biosimilar): If approved, SB3 would enter the US market via Merck/MSD as the sponsor, mirroring typical biosimilar regulatory and commercialization pathways, expanding available trastuzumab options for oncology patients.[2]

If you’d like, I can:

• Narrow to a specific biosimilar (SB3, SB5, or others) and summarize the latest regulatory status and expected timelines.
• Compile a compare-and-contrast table of Samsung Bioepis’ current US-regulatory status for each candidate.
• Pull the most recent official press releases or regulatory filings for precise dates and submission numbers.